The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

Respondents who said they used other drugs recreationally were also likelier to say they used ketamine during the past year ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

It is a hallucinogenic drug, and is a controlled substance designed for use as an aesthetics. It also has now been touted for ...

A multidisciplinary approach, including ketamine withdrawal and symptom management, is essential to mitigate long-term ...

Jeni Larmour died after taking ketamine on her first night at Newcastle University back in September 2020. Sandra Larmour, Jeni’s mum, is now calling for the reclassification of the drug, claiming ...

Recreational use of the anesthetic drug among U.S. adults increased 40% between 2021 and 2022, researchers say. That follows a nearly 82% increase in ketamine use from 2015 to 2019, results show.

According to a recent study, there have been shifts in both the patterns and correlates of ketamine use from 2015 to 2022.

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...